早期子宫内膜癌复发的本质——一项全国队列研究
该研究基于丹麦全国妇科癌症数据库2005-2009年诊断的2612例FIGO I-II期子宫内膜癌患者,分析3年内复发情况;183例(7%)复发,阴道复发者5年生存率64.8%,远处复发者17.5%;FIGO分期、Charlson合并症指数3、非子宫内膜样组织学及不在劳动力市场为复发预测因素。
要点
- 2612例早期子宫内膜癌中183例(7%)在3年内复发。
- 阴道复发5年生存率64.8%,远处复发17.5%。
- FIGO IB期复发OR 1.91,II期OR 3.91。
核心结论
- 未来研究应探索已识别预测因素的潜在机制,以改善复发预测并降低发病率和死亡率。
研究设计与样本
- 基于丹麦妇科癌症数据库的全国性历史队列研究,纳入2005-2009年诊断的FIGO I或II期子宫内膜癌女性2612例,随访生存至2014年12月31日。
主要发现
- 2612例中183例(7%)在初次治疗后3年内复发。
- 阴道复发者5年生存率为64.8%,远处复发者为17.5%。
- 复发预测因素包括FIGO分期(IB期OR 1.91,II期OR 3.91)、Charlson合并症指数3(OR 1.86)、非子宫内膜样组织学(OR 1.81)及不在劳动力市场(OR 1.81)。
- 阴道复发仅由FIGO分期预测(IB期OR 1.88,II期OR 2.79)。
- 宫外复发由FIGO分期(IB期OR 2.12,II期OR 3.31)、Charlson合并症指数3(OR 1.88)及非子宫内膜样组织学(OR 2.51)预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The aim of the study was to present a comprehensive analysis of disease recurrence in a large Danish cohort of women with early-stage endometrial cancer treated according to national guidelines. METHODS: All women diagnosed with stage I or II endometrial cancer in 2005-2009 were included in a population-based historical cohort derived from the Danish Gynaecological Cancer Database. Disease recurrence up to 3 years after the primary diagnosis was identified using national registers and hospital charts. Follow-up on survival ended on 31st December 2014. We evaluated the predictive value of clinico-pathological and sociodemographic variables using multivariate logistic regression. RESULTS: Recurrence within 3 years of the primary treatment was diagnosed in 183 (7%) of the included 2612 women. Site of recurrence significantly impacted on overall survival as the 5-year survival rate was 64.8% for women with vaginal recurrence and 17.5% in women with distant recurrence. Factors predictive of recurrence included the International Federation of Gynaecology and Obstetrics (FIGO) stage (OR: IB = 1.91, stage II = 3.91), Charlson comorbidity index of 3 (OR 1.86), non-endometrioid histology (OR 1.81) and being outside of the workforce (OR 1.81). Vaginal recurrence was predicted by FIGO stage only (OR: IB = 1.88, II = 2.79), while extra-vaginal recurrence was predicted by FIGO stage (OR: IB = 2.12, II = 3.31), Charlson comorbidity index of 3 (OR 1.88) and non-endometrioid histology (OR 2.51). CONCLUSIONS: Future research should seek to understand the underlying mechanisms of the identified predictive factors to improve recurrence prediction and to reduce morbidity and mortality.
引用
- Jeppesen MM, Jensen PT, Gilså Hansen D, et al. The nature of early-stage endometrial cancer recurrence-A national cohort study. Eur J Cancer. 2016. PMID: 27816832. doi:10.1016/j.ejca.2016.09.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。